Multivariate analysis on risk factors for postoperative ileus after lateral lumbar interbody fusion

Spine

Volumn 39, Issue 8, 2014, Pages 688-694

  Al Maaieh, Motasem A ^a   Du, Jerry Y ^a   Aichmair, Alexander ^a   Huang, Russel C ^a   Hughes, Alexander P ^a   Cammisa, Frank P ^a   Girardi, Federico P ^a   Sama, Andrew A ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Complications; Lateral lumbar interbody fusion; LLIF; Postoperative ileus; XLIF

Indexed keywords

ADULT; AGED; ANTERIOR SPINE FUSION; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; ICD-9-CM; INCIDENCE; LATERAL LUMBAR INTERBODY FUSION; LENGTH OF STAY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; ORTHOPEDIC SURGEON; POSTOPERATIVE ILEUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURGICAL PATIENT; UNIVARIATE ANALYSIS; CHI SQUARE DISTRIBUTION; GASTROINTESTINAL MOTILITY; ILEUS; LUMBAR VERTEBRA; MIDDLE AGED; PATHOPHYSIOLOGY; RISK; RISK ASSESSMENT; SPINE FUSION; STATISTICAL MODEL; SURGERY; TIME; TREATMENT OUTCOME; UNITED STATES;

AGED; CHI-SQUARE DISTRIBUTION; FEMALE; GASTROINTESTINAL MOTILITY; HUMANS; ILEUS; INCIDENCE; LENGTH OF STAY; LOGISTIC MODELS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEW YORK CITY; ODDS RATIO; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPINAL FUSION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925546636     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0000000000000238     Document Type: Article

References (35)

1. Than KD, Wang AC, Rahman SU, et al. Complication avoidance and management in anterior lumbar interbody fusion. Neurosurg Focus 2011; 31: E6.
2. Senagore AJ. Pathogenesis and clinical and economic consequences of postoperative ileus. Am J Health Syst Pharm 2007; 64 (suppl 13): S3-7.
3. Youssef JA, McAfee PC, Patty CA, et al. Minimally invasive surgery: lateral approach interbody fusion: results and review. Spine (Phila Pa 1976) 2010; 35 (suppl 26): S302-11.
4. Gumbs AA, Hanan S, Yue JJ, et al. Revision open anterior approaches for spine procedures. Spine J 2007; 7: 280-5.
5. Lykissas MG, Cho W, Aichmair A, et al. Is there any relation between the amount of curve correction and postoperative neurologic deficit or pain in patients undergoing standalone lateral lumbar interbody fusion? Spine (Phila Pa 1976) 2013.
6. Lykissas MG, Aichmair A, Hughes AP, et al. Nerve injury after lateral lumbar interbody fusion: a review of 919 treated levels with identification of risk factors. Spine J 2013; S1529-9430: 00769-9.
7. Santos ER, Pinto MR, Lonstein JE, et al. Revision lumbar arthrod-esis for the treatment of lumbar cage pseudoarthrosis: complications. J Spinal Disord Tech 2008; 21: 418-21.
8. Scaduto AA, Gamradt SC, Yu WD, et al. Perioperative complications of threaded cylindrical lumbar interbody fusion devices: anterior versus posterior approach. J Spinal Disord Tech 2003; 16: 502-7.
9. Brau SA. Mini-open approach to the spine for anterior lumbar interbody fusion: description of the procedure, results and complications. Spine J 2002; 2: 216-23.
10. Faciszewski T, Winter RB, Lonstein JE, et al. The surgical and medical perioperative complications of anterior spinal fusion surgery in the thoracic and lumbar spine in adults. A review of 1223 procedures. Spine (Phila Pa 1976) 1995; 20: 1592-9.
11. Rajaraman V, Vingan R, Roth P, et al. Visceral and vascular complications resulting from anterior lumbar interbody fusion. J Neurosurg 1999; 91 (suppl 1): 60-4.
12. Fineberg SJ, Nandyala SV, Kurd MF, et al. Incidence and risk factors for post-operative ileus following anterior, posterior, and circumferential lumbar fusion. Spine J 2013; S1529-9430: 01610-0.
13. Delaney CP, Senagore AJ, Viscusi ER, et al. Postoperative upper and lower gastrointestinal recovery and gastrointestinal morbidity in patients undergoing bowel resection: pooled analysis of placebo data from 3 randomized controlled trials. Am J Surg 2006; 191: 315-9.
14. Kehlet H, Holte K. Review of postoperative ileus. Am J Surg 2001; 182 (suppl 5A): 3S-10S.
15. Kraft M, Erstad BL, Matuszewski K. Improving postoperative ileus outcomes. U.S. Pharmacist 2005.
16. Shindo T, Futagami S, Hiratsuka T, et al. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion 2009; 79: 65-72.
17. Edholm T, Levin F, Hellström PM, et al. Ghrelin stimulates motility in the small intestine of rats through intrinsic cholinergic neurons. Regul Pept 2004; 121: 25-30.
18. Inui A, Asakawa A, Bowers CY, et al. Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J 2004; 18: 439-56.
19. Charoenthongtrakul S, Giuliana D, Longo KA, et al. Enhanced gas-trointestinal motility with orally active ghrelin receptor agonists. J Pharmacol Exp Ther 2009; 329: 1178-86.
20. PIMC National Experts' Clinical Consensus Panel and Scientific Roundtable. Postoperative ileus: profiles, risk factors, and defini-tions-a framework for optimizing surgical outcomes in patients undergoing major abdominal and colorectal surgery. In: Clinical Consensus Update in General Surgery. May 1, 2006. Available at http://www.clinicalwebcasts.com/pdfs/GenSurg-WEB.pdf. Accessed May 1, 2006.
21. Walters JB, Montagnini M. Current concepts in the management of opioid-induced constipation. J Opioid Manag 2010; 6: 435-44.
22. Anissian L, Schwartz HW, Vincent K, et al. Subcutaneous meth-ylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. J Hosp Med 2012; 7: 67-72.
23. Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med 1999; 341: 137-41.
24. Eisen GM, Baron TH, Dominitz JA, et al. Acute colonic pseudo-obstruction. Gastrointest Endosc 2002; 56: 789-92.
25. Penner RM, Jacka MJ, Brindley PG. Best evidence in critical care medicine: medical therapy of acute colonic pseudo-obstruction: a moving experience. Can J Anaesth 2005; 52: 542-3.
26. Saunders MD, Kimmey MB. Systematic review: acute colonic pseudo-obstruction. Aliment Pharmacol Ther 2005; 22: 917-25.
27. Taylor P. Agents acting at the neuromuscular junction and auto-nomic ganglia. Goodman & Gilman's the Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 227.
28. Taylor P. Anticholinesterase agents. Goodman & Gilman's the Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 2006: 201-16.
29. Thomas JR, Cooney GA, Slatkin NE. Palliative care and pain: new strategies for managing opioid bowel dysfunction. J Palliat Med 2008; 11 (suppl 1): S1-19; quiz S21-12.
30. Tack J. Current and future therapies for chronic constipation. Best Pract Res Clin Gastroenterol 2011; 25: 151-8.
31. Bader S, Jaroslawski K, Blum HE, et al. Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide. Clin Med Insights Oncol 2011; 5: 201-11.
32. Emmanuel A. Current management strategies and therapeutic targets in chronic constipation. Therap Adv Gastroenterol 2011; 4: 37-48.
33. Amitiza (lubiprostone). Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2013.
34. Entereg (alvimopan). Lexington, MA: Cubist Pharmaceuticals, Inc.; 2012.
35. Relistor (methylnaltrexone bromide). Raleigh, NC: Salix Pharmaceuticals Inc; 2012.